# Early signs of weak monsoon impact 

## FMCG sales grow $\mathbf{1 2 . 7 \%}$ in July, much below trend

July sales growth of $12.7 \%$ is lower than the last six month trend of high-teens growth. Most companies showed a MoM decline. We believe this could be early indication of a weak monsoon impacting top-line growth for FMCG and we will watch out for the sales growth trend in coming months. Tata Tea, Godrej and P\&G continue to do well. Nestle, Colgate, Marico and Dabur showed average performance. HUL, Nirma and Britannia disappointed with mid-to-low-single-digit growth in July.

HUL - Sales gr slows down further to 7\% vs. 13\% over last yr Initiatives taken by HUL to improve sales growth are yet to show positive results, as sales declined for fourth straight month. Volume growth remains negative for Soaps, Laundry, Toothpaste, Tea and Coffee. Fastest-growing categories in terms of value growth were Laundry, Skin Care and Shampoos, while Tea and Ketchups had single-digit growth. Sales declined in July for Soaps, Coffee and Toothpaste.

## HUL - Market share trend was a mixed bag

July was a mixed bag, with Laundry, Shampoos, Tea and Ketchups showing gains, while Soaps, Toothpaste, Skin Care and Coffee continued to lose market share. Over last one year, HUL has lost market share across all key categories Soaps (570bps), Detergents (210bps), Shampoos (10bps), Toothpaste (220bps), Skin Care (420bps), Tea (260bps), Coffee (770bps) and Ketchups (160bps). We believe volume gr and market share recovery will be slow and expensive for HUL.

## Nestle - sales growth weakens sharply

Sales growth decline continued for Nestle and growth in July was 12\%. This is significantly lower than AC Nielsen reported YTD sales growth. Market shares showed mixed trends with gains in Coffee and Chocolates, while Noodles and Ketchups lost share. The trend over the last 12 months has been negative, with gains in Coffee, but declines in Chocolates, Noodles and Ketchups.

## Colgate - sales gr holds up, with mixed market share trends

 July sales grew $10 \%$. Colgate was one of the two companies to show MoM improvement in sales gr. Market share trends were mixed with Toothpaste gaining 30bps but Toothbrush lost 40bps and Toothpowder lost 90bps in July. Toothpaste is running at all-time-high market share and further improvement looks difficult.
## Dabur - sales gr stable, with positive market share trends

July sales grew 10\%, marginally lower that growth reported by AC Nielsen for last one year. Market shares improved for Shampoos and Toothpaste, but there were declines in Toothpowder and Chyawanprash. Over the last one year, Dabur has gained market share in Toothpaste (90bps) and Shampoos (90bps), but lost shares in Chyawanprash (470bps) and Toothpowder (130bps).

## Bank of America Merrill Lynch

Anuj Bansal >>
+91 2266328690
Research Analyst
DSP Merrill Lynch (India)
anuj_bansal@ml.com

Table 1: Market Share trends

|  | Jul-08 | Nov-08 | Mar-09 | Jul-09 |
| :--- | ---: | ---: | ---: | ---: |
| HUL |  |  |  |  |
| - Soaps | 50.3 | 49.8 | 47.4 | 44.6 |
| - Detergents | 39.4 | 39.9 | 36.7 | 37.3 |
| - Shampoo | 45.8 | 45.9 | 44.9 | 45.6 |
| - Toothpaste | 29.6 | 28.8 | 27.8 | 27.4 |
| - Skincare | 51.8 | 50.9 | 46.6 | 47.6 |
| - Tea | 24.6 | 24.0 | 22.9 | 22.0 |
| P\&G |  |  |  |  |
| - Detergents | 15.6 | 14.5 | 14.0 | 14.5 |
| - Shampoo | 24.7 | 23.9 | 24.8 | 23.7 |
| Godrej Cons. |  |  |  |  |
| - Soaps | 9.6 | 9.4 | 9.6 | 10.4 |
| Dabur |  |  |  |  |
| - Toothpaste | 9.0 | 9.3 | 9.7 | 10.0 |
| - Shampoo | 5.6 | 5.7 | 5.7 | 6.5 |
| - Ch'prash | 61.9 | 61.1 | 59.3 | 57.2 |
| Nestle |  |  |  |  |
| - Coffee | 37.4 | 43.3 | 42.0 | 42.9 |
| - Chocolates | 25.2 | 23.1 | 24.5 | 24.8 |
| Colgate |  |  |  |  |
| - Toothpaste | 48.0 | 48.6 | 49.2 | 50.0 |
| - Toothpowder | 45.3 | 45.8 | 45.5 | 44.1 |
| Tata Tea |  |  |  |  |
| - Tea | 20.9 | 21.9 | 22.1 | 21.1 |
| Source: Ac Nelsen |  |  |  |  |

>> Employed by a non-US affiliate of MLPF\&S and is not registered/qualified as a research analyst under the FINRA rules.
Refer to "Other Important Disclosures" for information on certain Merrill Lynch entities that take responsibility for this report in particular jurisdictions.
Merrill Lynch does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.
Refer to important disclosures on page 10 to 11.

Total sales growth came in at 12.7\% much below the mid-to-high-teens growth rate reported over last few months. We believe this could be early indication of a weak monsoon impacting sales growth in FMCG. We need to watch out for sales growth trends in coming months to confirm the impact.

Sales growth (\%) in J uly 2009 - Weakness for most companies

Tata Tea - 22.5
Godrej - 16.8
P\&G-14.2
Nestle - 12.2
Colgate - 9.9
Dabur-9.8
Marico-8.9
HUL-6.9

HUL continues to lose market share, with a 90bps decline in July. Overall, it has lost 570bps sine July'08. Godrej gained 30bps in July, taking up its overall gain since July' 08 to $80 b p s$. HUL continues to suffer from steep price increases it took during 2 HCY 08 . Godrej did not match these price hikes and gained from the price differential created by this.

## Sales Growth Trends

Chart 1: FMCG Sales Growth Trends


Source: AC Nielsen

Chart 2: Company Sales Growth Trend


Source: AC Nielsen

## Market Share Trend

Chart 3: Soaps market share trends


[^0]HUL gained 60bps market share in J uly and P\&G gained 100bps, with Nirma losing 70bps. Overall, P\&G has come off from its peak market share of Jul'08, and has lost 110bps since. For HUL, it has seen a declining trend, with 210bps market share loss in last 12 months.

HUL gained 20bps, while P\&G and Dabur remained flat in J uly. HUL (10bps) has lost market share since July' 08, with Dabur gaining 90bps and P\&G losing 100bps.

Col gate gained 30bps in July. In an impressive run since July' 08, it has gained 200bps market share. Dabur gained 10bps in J uly, taking up its last 12month gains to an impressive 90bps. HUL continued to lose share and was down 40bps in July. Its longer-term performance has been disappointing, with a 220 bps decline since July' 08 .

Chart 4: Detergents Market Share Trend


Source: AC Nielsen

Chart 5: Shampoos Market Share Trend


Source: AC Nielsen

Chart 6: Toothpaste Market Share Trend


[^1]Colgate lost 90bps and Dabur lost 20bps in J uly. In the Ionger term, Colgate has lost 120bps and Dabur has lost 130bps since July' 08 . Overall, the category itself is facing problems, as rural consumers are migrating from toothpowders to low-cost toothpastes.

HUL lost 30bps in J uly, reversing the recovery trend of last month. Overall, in a largely negative trend, HUL has lost 420bps since J uly' 08.

HUL gained 80bps, while Tata Tea lost 30bps market share in July. However, in the Ionger run, HUL has now lost 260bps since July' 08. Tata Tea, on the other hand, has done well, with a 20bps gain over the same period.

## Chart 7: Toothpowder Market Share Trend



Source: AC Nielsen

## Chart 8: Skincare Market Share Trend



Source: AC Nielsen

## Chart 9: Tea Market Share Trend



Source: AC Nielsen

## Chart 10: Coffee Market Share Trend



Source: AC Nielsen

## Chart 11: Ketchup Market Share Trend



Source: AC Nielsen

## Chart 12: Noodles Market Share Trend



Source: AC Nielsen

Nestle gained 20bps in July. It has been a volatile trend over last couple of years. However, there appears to be a structural downward bias to this trend. Nestle has lost 50 bps in last 12 months.

Dabur lost a massive 480bps in J uly and gave up all the gains of last month. This is in line with Dabur's trend of losing market share during the off-season, when the lower-cost alternatives perform better. Over the last 12 months, Dabur has lost 470bps in this category.

## Chart 13: Chocolates Market Share Trend



Source: AC Nielsen

## Chart 14: Chyawanprash Market Share Trend



Source: AC Nielsen

## Category Growth Trend (Y-0-Y)

Chart 15: Soaps Value Growth Trend


Source: AC Nielsen

Chart 16: Soaps Volume Growth Trend


## Chart 17: Detergents Value Growth Trend



Source: AC Nielsen

## Chart 19: Shampoo Value Growth Trend



Source: AC Nielsen

Chart 21: Toothpaste Value Growth Trend


Source: AC Nielsen

Chart 18: Detergents Volume Growth Trend


Source: AC Nielsen

Chart 20: Shampoo Volume Growth Trend


Source: AC Nielsen

Chart 22: Toothpaste Volume Growth Trend

$\rightarrow$ HUL $\longrightarrow$ Colgate $\longrightarrow$ Dabur (RHS)

Source: AC Nielsen

Chart 23: Skincare Value Growth Trend


Source: AC Nielsen

Chart 25: Tea Value Growth Trend


Source: AC Nielsen

Chart 24: Skincare Volume Growth Trend


Source: AC Nielsen

## Chart 26: Tea Volume Growth Trend



Source: AC Nielsen

## Special Disclosures

In accordance with the SEBI (Foreign Institutional Investors) Regulations and with guidelines issued by the Securities and Exchange Board of India (SEBI), foreign investors (individuals as well as institutional) that wish to transact the common stock of Indian companies must have applied to, and have been approved by SEBI and the Reserve Bank of India (RBI). Each investor who transacts common stock of Indian companies will be required to certify approval as a foreign institutional investor or as a sub-account of a foreign institutional investor by SEBI and RBI. Certain other entities are also entitled to transact common stock of Indian companies under the Indian laws relating to investment by foreigners. Merrill Lynch reserves the right to refuse copy of research on common stock of Indian companies to a person not resident in India.
American Depositary Receipts (ADR) representing such common stock are not subject to these Indian law restrictions and may be transacted by investors in accordance with the applicable laws of the relevant jurisdiction.
Global Depository Receipts (GDR) and the Global Depository Shares of Indian companies, Indian limited liability corporations, have not been registered under the U.S. Securities Act of 1933, as amended, and may only be transacted by persons in the United States who are Qualified Institutional Buyers (QIBs) within the meaning of Rule 144A under the Securities Act. Accordingly, no copy of any research report on Indian companies' GDRs will be made available to persons who are not QIBs.

## Important Disclosures

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of a stock's: (i) absolute total return potential and (ii) attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). There are three investment ratings: 1-Buy stocks are expected to have a total return of at least $10 \%$ and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3-Underperform stocks are the least attractive stocks in a coverage cluster. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).
Investment rating Total return expectation (within 12-month period of date of initial rating) Ratings dispersion guidelines for coverage cluster*

| Buy | $\geq 10 \%$ | $\leq 70 \%$ |
| :---: | :---: | :---: |
| Neutral | $\geq 0 \%$ | $\leq 30 \%$ |
| Underperform | N/A | $\geq 20 \%$ |

* Ratings dispersions may vary from time to time where BAS-ML Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

INCOME RATINGS, indicators of potential cash dividends, are: 7-same/higher (dividend considered to be secure), 8-samellower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BAS-ML Comment referencing the stock.

## Other Important Disclosures

Merrill Lynch Research policies relating to conflicts of interest are described at http://www.ml.com/media/43347.pdf.
"Merrill Lynch" includes Merrill Lynch, Pierce, Fenner \& Smith Incorporated ("MLPF\&S") and its affiliates, including BofA (defined below). "BofA" refers to Banc of America Securities LLC ("BAS"), Banc of America Securities Limited ("BASL"), Banc of America Investment Services, Inc ("BAI") and their affiliates. Investors should contact their Merrill Lynch or BofA representative if they have questions concerning this report.

Information relating to Non-US affiliates of Merrill Lynch and Distribution of Affiliate Research Reports:
MLPF\&S, BAS, BAI, and BASL distribute, or may in the future distribute, research reports of the following non-US affiliates in the US (short name: legal name): Merrill Lynch (France): Merrill Lynch Capital Markets (France) SAS; Merrill Lynch (Frankfurt): Merrill Lynch International Bank Ltd, Frankfurt Branch; Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd; Merrill Lynch (Milan): Merrill Lynch International Bank Limited; MLPF\&S (UK): Merrill Lynch, Pierce, Fenner \& Smith Limited; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited; Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd; Merrill Lynch (Canada): Merrill Lynch Canada Inc; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa; Merrill Lynch (Argentina): Merrill Lynch Argentina SA; Merrill Lynch (Japan): Merrill Lynch Japan Securities Co, Ltd; Merrill Lynch (Seoul): Merrill Lynch International Incorporated (Seoul Branch); Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd.; DSP Merrill Lynch (India): DSP Merrill Lynch Limited; PT Merrill Lynch (Indonesia): PT Merrill Lynch Indonesia; Merrill Lynch (KL) Sdn. Bhd.: Merrill Lynch (Malaysia); Merrill Lynch (Israel): Merrill Lynch Israel Limited; Merrill Lynch (Russia): Merrill Lynch CIS Limited, Moscow; Merrill Lynch (Turkey): Merrill Lynch Yatirim Bankasi A.S.; Merrill Lynch (Dubai): Merrill Lynch International Bank Ltd, Dubai Branch; MLPF\&S (Zürich rep. office): MLPF\&S Incorporated Zürich representative office.

This research report has been approved for publication in the United Kingdom by Merrill Lynch, Pierce, Fenner \& Smith Limited and BASL, which are authorized and regulated by the Financial Services Authority; has been considered and distributed in Japan by Merrill Lynch Japan Securities Co, Ltd and Banc of America Securities - Japan, Inc., registered securities dealers under the Financial Instruments and Exchange Law in Japan; is distributed in Hong Kong by Merrill Lynch (Asia Pacific) Limited and Banc of America Securities Asia Limited, which are regulated by the Hong Kong SFC and the Hong Kong Monetary Authority; is issued and distributed in Taiwan by Merrill Lynch Securities (Taiwan) Ltd.; is issued and distributed in Malaysia by Merrill Lynch (KL) Sdn. Bhd., a licensed investment adviser regulated by the Malaysian Securities Commission; is issued and distributed in India by DSP Merrill Lynch Limited; and is issued and distributed in Singapore by Merrill Lynch International Bank Limited (Merchant Bank), Merrill Lynch (Singapore) Pte Ltd (Company Registration No.'s F 06872E and 198602883D respectively) and Bank of America Singapore Limited (Merchant Bank). Merrill Lynch International Bank Limited (Merchant Bank), Merrill Lynch (Singapore) Pte Ltd and Bank of America Singapore Limited (Merchant Bank) are regulated by the Monetary Authority of Singapore. Merrill Lynch Equities (Australia) Limited (ABN 65006276795 ), AFS License 235132 provides this report in Australia in accordance with section 911B of the Corporations Act 2001 and neither it nor any of its affiliates involved in preparing this research report is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this report in Brazil.

This research report has been prepared and issued by MLPF\&S and/or one or more of its non-US affiliates. MLPF\&S is the distributor of this research report in the US and accepts full responsibility for research reports of its non-US affiliates distributed to MLPF\&S clients in the US. Any US person (other than BAS, BAI and their respective clients) receiving this research report and wishing to effect any transaction in any security discussed in the report should do so through MLPF\&S and not such foreign affiliates.

BAS distributes this research report to its clients and to its affiliate BAI and accepts responsibility for the distribution of this report in the US to BAS clients, but not to the clients of BAI. BAI is a registered broker-dealer, member of FINRA and SIPC, and is a non-bank subsidiary of Bank of America, N.A. BAI accepts responsibility for the distribution of this report in the US to BAI clients. Transactions by US persons that are BAS or BAI clients in any security discussed herein must be carried out through BAS and BAI, respectively.

## General Investment Related Disclosures:

This research report provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this report.

Securities and other financial instruments discussed in this report, or recommended, offered or sold by Merrill Lynch, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

UK Readers: The protections provided by the U.K. regulatory regime, including the Financial Services Scheme, do not apply in general to business coordinated by Merrill Lynch entities located outside of the United Kingdom. These disclosures should be read in conjunction with the BASL general policy statement on the handling of research conflicts, which is available upon request.

Officers of MLPF\&S or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

Merrill Lynch is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. Merrill Lynch may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

Merrill Lynch, through business units other than BAS-ML Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented in this report. Such ideas or recommendations reflect the different time frames, assumptions, views and analytical methods of the persons who prepared them, and Merrill Lynch is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this report.

Copyright and General Information regarding Research Reports:
Copyright 2009 Merrill Lynch, Pierce, Fenner \& Smith Incorporated. All rights reserved. iQmethod, iQmethod 2.0, iQprofile, iQtoolkit, iQworks are service marks of Merrill Lynch \& Co., Inc. iQanalytics®, iQcustom®, iQdatabase® are registered service marks of Merrill Lynch \& Co., Inc. This research report is prepared for the use of Merrill Lynch clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Merrill Lynch. Merrill Lynch research reports are distributed simultaneously to internal and client websites and other portals by Merrill Lynch and are not publiclyavailable materials. Any unauthorized use or disclosure is prohibited. Receipt and review of this research report constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets) without first obtaining expressed permission from an authorized officer of Merrill Lynch.

Materials prepared by Merrill Lynch research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of Merrill Lynch, including investment banking personnel. To the extent this report discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this report. Merrill Lynch research personnel's knowledge of legal proceedings in which any Merrill Lynch entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving companies mentioned in this report is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of Merrill Lynch in connection with the legal proceedings or matters relevant to such proceedings.

This report has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of MLPF\&S, any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). Merrill Lynch policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to Merrill Lynch and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This report may contain links to third-party websites. Merrill Lynch is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this report and is not incorporated by reference into this report. The inclusion of a link in this report does not imply any endorsement by or any affiliation with Merrill Lynch. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. Merrill Lynch is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and Merrill Lynch policyrelated restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports may contain discussions and/or investment opinions relating to securities, financial instruments and/or issuers that are no longer current. Always refer to the most recent research report relating to a company or issuer prior to making an investment decision.

In some cases, a company or issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such company or issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BAS, BAI, MLPF\&S or any of their affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither Merrill Lynch nor any officer or employee of Merrill Lynch accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents.


[^0]:    Source: AC Nielsen

[^1]:    Source: AC Nielsen

